Pyxis Oncology Announces Participation in Future Investor Events
Pyxis Oncology, Inc. (Nasdaq: PYXS), a company dedicated to developing innovative ADC therapeutics for challenging cancers, has exciting news for investors. The company's President and CEO, Dr. Lara S. Sullivan, will engage in notable fireside chats and take part in one-on-one investment meetings at two significant investor conferences.
Key Dates for Investor Engagement
The upcoming conferences are excellent opportunities for interested investors to gain insights into Pyxis Oncology's strategic direction and advancements in therapeutic development. The details are as follows:
RBC Capital Markets Global Healthcare Conference
This event is scheduled for a Wednesday and will take place in one of the major U.S. financial hubs. Dr. Sullivan's participation is set for the time just after lunch, making it a prime session for engaged discussions.
Jefferies Global Healthcare Conference
Shortly after the RBC event, Pyxis will also be featured at another conference, opening the floor for productive investor interactions. This opportunity allows for deeper exploration of their innovative approaches and ongoing projects.
Insights on Pyxis Oncology’s Mission
At the heart of Pyxis Oncology is a commitment to confront tough-to-treat cancers with cutting-edge therapeutic options. The firm has made remarkable strides in developing next-generation therapeutics. Noteworthy among their projects is micvotabart pelidotin (MICVO), which is currently in Phase 1 clinical trials targeting solid tumors, with a keen focus on recurrent and metastatic head and neck squamous cell carcinoma.
Collaboration with Keytruda
Furthermore, the company has initiated a Phase 1/2 study combining MICVO with Merck's leading anti-PD-1 therapy, KEYTRUDA, in patients with advanced forms of cancer. This combination therapy signifies the company’s dedication to exploring synergistic treatments that can yield better patient outcomes.
Stay Updated with Pyxis Oncology
As developments unfold, detailed updates will be available on Pyxis Oncology’s website in the Investor Relations section. This includes both live broadcasts of the fireside chats and recordings, ensuring that all interested stakeholders can stay informed about the latest advancements and corporate strategies.
Learn More
The company encourages everyone to visit their website for comprehensive information regarding their latest projects and initiatives. It’s a fantastic resource for understanding their ongoing efforts to innovatively combat cancer.
Contact Information for Pyxis Oncology
For inquiries, investors and interested parties can reach out to Pamela Connealy, the CFO and COO of Pyxis Oncology, via email. She is dedicated to ensuring transparent communication with stakeholders, fostering a deeper understanding of the company's mission.
Frequently Asked Questions
What is Pyxis Oncology known for?
Pyxis Oncology specializes in developing innovative antibody-drug conjugates (ADCs) to address difficult-to-treat cancers.
Who will represent Pyxis at the investor conferences?
Dr. Lara S. Sullivan, the President and CEO, will represent the company during the upcoming investor events.
What is micvotabart pelidotin (MICVO)?
MICVO is Pyxis Oncology's lead candidate, currently in clinical trials targeting hard-to-treat solid tumors.
How can I stay updated on Pyxis Oncology’s news?
You can follow updates and news releases on their official website and through their Investor Relations page.
Where can I find more information about their products?
The details about their therapeutics and clinical developments can be found on the Pyxis Oncology website, offering insights into their current projects and potential future advancements.
